AVDL VS PHR Stock Comparison

Performance

AVDL
100/100

AVDL returned 58.04% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.

PHR
10/100

PHR returned -36.76% in the last 12 months. Based on SPY's performance of -13.33%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

AVDL
80/100

5 analysts offer 12-month price targets for AVDL. Together, they have an average target of 10.67, the most optimistic target put AVDL at 12 within 12-months and the most pessimistic has AVDL at 9.

PHR

"Analyst Price Targets" not found for PHR

Sentiment

AVDL
70/100

AVDL had a bullish sentiment score of 70.23% across Twitter and StockTwits over the last 12 months. It had an average of 6.78 posts, 3.03 comments, and 4.97 likes per day.

PHR

"Sentiment" not found for PHR

Technicals

AVDL
11/100

AVDL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

PHR
50/100

PHR receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

AVDL
10/100

AVDL has missed earnings 7 times in the last 20 quarters.

PHR
10/100

PHR has missed earnings 6 times in the last 20 quarters.

Profit

AVDL
10/100

Out of the last 20 quarters, AVDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.

PHR
10/100

Out of the last 20 quarters, PHR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

AVDL
56/100

AVDL has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

PHR
46/100

PHR has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

Dividend

AVDL

"Dividend" not found for AVDL

PHR
54/100

PHR's most recent dividend was $2.20 per share, based on a share price of $15.81. It was a payout ratio of 26.81% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Avadel Pharmaceuticals plc Ordinary Share Summary

Nasdaq / AVDL

Healthcare

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Phreesia, Inc. Summary

New York Stock Exchange / PHR

Healthcare

Medical - Healthcare Information Services

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.

Power up your portfolio